Konstantin A. Kaperiz

Konstantin A. Kaperiz

Auto-generated profile, based on publicly available information

Konstantin A. Kaperiz

National Medical Research Center for Therapy and Preventive Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2020 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
VMVladimir P. Minaev
Vladimir P. Minaev
NMNikita Minaev
Nikita Minaev
VBVadim Yu Bogachev
Vadim Yu Bogachev
KKKonstantin A. Kaperiz
Konstantin A. Kaperiz
Vladimir YusupovVladimir Yusupov
Vladimir Yusupov

8 April 2021 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
VMVladimir P. Minaev
Vladimir P. Minaev
NMNikita Minaev
Nikita Minaev
VBVadim Yu Bogachev
Vadim Yu Bogachev
KKKonstantin A. Kaperiz
Konstantin A. Kaperiz
Vladimir YusupovVladimir Yusupov
Vladimir Yusupov

29 June 2020 in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Verified
Journal Article
Open access
PDF file
VBVadim Yu Bogachev
Vadim Yu Bogachev
DRD. A. Rosukhovski
D. A. Rosukhovski
DBD. A. Borsuk
D. A. Borsuk
OSO. A. Shonov
O. A. Shonov
HMH. P. Manjikian
H. P. Manjikian
ЕБЕ. Ю. Бережной
Е. Ю. Бережной
Recently collated scientific data on the management of C1 clinical class of chronic venous disorders; wide prevalence of the disease and high variability amongst medical practitioners in relation to managing this category of patients and absence of any regulatory documents has prompted the development of clinical guidelines for the treatment of patients with reticular varicose veins and telangiectasias of the lower extremities and various parts of the body. These guidelines have been developed by a self-regulated organization Association “The National College of Phlebology”. The purpose of the de novo guidelines is to systematize the existing evidence and offer minimal standards of care for chronic venous disorders in C1 patients.

1 March 2023 in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Verified
Journal Article
Open access
PDF file
VMV. P. Minaev
V. P. Minaev
VBVadim Yu Bogachev
Vadim Yu Bogachev
KKK. A. Kaperiz
K. A. Kaperiz
The article discusses the evolution of the endovenous laser ablation technique for the treatment of varicose vein disease of lower extremities. The history of studies aimed at improving the endovenous laser ablation is provided. The authors described the features of endovenous laser ablation with wavelengths from λ = 0.445 to 1.94 µm, alongside with edge- and radial-emitting working fibers, as well as fibers with radiation absorption at its distal end. The physical and biophysical mechanisms of the most popular to-date method for outpatient treatment of varicose vein disease of lower extremities are reviewed. The propagation process of laser radiation in the scattering medium is described, and the important role of the radiation scattering effect on the depth of its penetration into biological tissues is shown. The processes that take place during endovenous laser ablation are considered. The difference in physical processes that take place during the use of laser radiation mainly absorbed by hemoglobin (hemoglobin-absorbed range) and by water (water-absorbed range) is described. Expedience of simulating the processes that take place during endovenous laser ablation with the use of blood plasma has been substantiated. The blood plasma simulation demonstrated the decisive action of laser-induced boiling on thermal damage to the vein wall, which causes its fibrous transformation. It has been shown that the use of radial-emitting fibres during intense boiling generates steam bubbles around the site of radiation coupling. The contents of such steam bubbles do not absorb radiation, which thus reaches the venous wall, causing its symmetrical thermal damage. The advantages of using water-absorbing radiation with a wavelength of λ = 1.94 µm in conjunction with a radial-emitting fibre have been substantiated.

16 January 2021 in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Verified
Journal Article
Open access
PDF file
VBVadim Yu Bogachev
Vadim Yu Bogachev
DRD. A. Rosukhovski
D. A. Rosukhovski
DBD. A. Borsuk
D. A. Borsuk
OSO. A. Shonov
O. A. Shonov
HMH. P. Manjikian
H. P. Manjikian
ЕБЕ. Ю. Бережной
Е. Ю. Бережной
Recently collated scientific data on the management of C1 clinical class of chronic venous disorders; wide prevalence of the disease and high variability amongst medical practitioners in relation to managing this category of patients and absence of any regulatory documents has prompted the development of clinical guidelines for the treatment of patients with reticular varicose veins and telangiectasias of the lower extremities and various parts of the body. These guidelines have been developed by a self-regulated organization Association “The National College of Phlebology”. The purpose of the de novo guidelines is to systematize the existing evidence and offer minimal standards of care for chronic venous disorders in C1 patients.

17 January 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
KKK. A. Kaperiz
K. A. Kaperiz
ARA. O. Rastatueva
A. O. Rastatueva
IYI. S. Yavelov
I. S. Yavelov
ODOxana M. Drapkina
Oxana M. Drapkina
Thrombophlebitis of the superficial lower limb veins is one of the most common complications of chronic vein disease. Nowadays a long-term (at least 45 days) subcutaneous injection of fondaparinux sodium or heparin in combination with elastic compression of the limb is recommended for treatment of superficial vein thrombosis with a moderate risk of thrombus propagation to deep venous system. However, long-term use of anticoagulants is not always possible and sometimes contraindicated. Endovenous laser ablation (EVLA) around thrombus-free junction of great or small saphenous veins without subsequent long-term use of anticoagulants seems to be a promising intervention for treatment of acute thrombophlebitis of varicose superficial veins.The prospective single-center randomized open-label clinical trial was dedicated for comparison the efficacy and safety of three following treatments options for patients with acute thrombosis of the varicose great saphenous vein and location of thrombi in the trunk and/ or its large inflows: EVLA close to saphenous vein junction without anticoagulation, EVLA and 7 days of anticoagulation and noninvasive treatment with anticoagulation for 45 days (subcutaneous injections of the fondaparinux 2,5 mg). Class 2 compression stockings are used in all patients. Adverse outcomes are recorded at 7, 45 and 90 days after randomization. These include the progression of superficial vein thrombosis, recurrent superficial vein thrombosis, thrombosis involvement of the superficial segment of the perforating vein up to the fascia, deep vein thrombosis according to compression ultrasound, and pulmonary embolism with symptoms. Bleedings according to the World Society of Thrombosis and Hemostasis and the Academic Research Consortium classification as well other complications are also recorded. The first 30 patients included in the study have a low incidence of venous thrombosis risk factors and localization of the thrombus relatively far from the saphenofemoral junction. EVLA resulted in persistent cessation of venous blood flow at the intervention site. New episodes of venous thrombosis were noted only in the group of medical treatment — deep vein thrombosis of the contralateral tibia 5 days after stopping of 45-day treatment with fondaparinux and thrombus in the recanalized inflow of the great saphenous vein without involving its trunk at the 21st day after stopping of 45-day injection of fondaparinux. There were no complications in the area of intervention and bleedings.